124 related articles for article (PubMed ID: 7829269)
1. Effect of VK framework-1 glycosylation on the binding affinity of lymphoma-specific murine and chimeric LL2 antibodies and its potential use as a novel conjugation site.
Leung SO; Dion AS; Pellegrini MC; Losman MJ; Grebenau RC; Goldenberg DM; Hansen HJ
Int J Cancer; 1995 Feb; 60(4):534-8. PubMed ID: 7829269
[TBL] [Abstract][Full Text] [Related]
2. Chimerization of LL2, a rapidly internalizing antibody specific for B cell lymphoma.
Leung SO; Shevitz J; Pellegrini MC; Dion AS; Shih LB; Goldenberg DM; Hansen HJ
Hybridoma; 1994 Dec; 13(6):469-76. PubMed ID: 7737671
[TBL] [Abstract][Full Text] [Related]
3. Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2.
Leung SO; Goldenberg DM; Dion AS; Pellegrini MC; Shevitz J; Shih LB; Hansen HJ
Mol Immunol; 1995 Dec; 32(17-18):1413-27. PubMed ID: 8643111
[TBL] [Abstract][Full Text] [Related]
4. Development and evaluation of the specificity of a rat monoclonal anti-idiotype antibody, WN, to an anti-B-cell lymphoma monoclonal antibody, LL2.
Losman MJ; Leung SO; Shih LB; Shevitz J; Shukla R; Haraga L; Goldenberg DM; Hansen HJ
Cancer Res; 1995 Dec; 55(23 Suppl):5978s-5982s. PubMed ID: 7493380
[TBL] [Abstract][Full Text] [Related]
5. Engineering a unique glycosylation site for site-specific conjugation of haptens to antibody fragments.
Leung S; Losman MJ; Govindan SV; Griffiths GL; Goldenberg DM; Hansen HJ
J Immunol; 1995 Jun; 154(11):5919-26. PubMed ID: 7751635
[TBL] [Abstract][Full Text] [Related]
6. A V kappa-J kappa junctional change in an antidigoxin recombinant antibody destroys digoxin-binding activity.
Hudson NW; Bruccoleri RE; Steinrauf LK; Hamilton JA; Mudgett-Hunter M; Margolies MN
J Immunol; 1990 Oct; 145(8):2718-24. PubMed ID: 2120338
[TBL] [Abstract][Full Text] [Related]
7. Cloning of cDNAs encoding the variable domains of antibody KC4G3 and construction of a chimeric antibody.
Couto JR; Blank EW; Peterson JA; Ceriani RL
Hybridoma; 1993 Aug; 12(4):485-9. PubMed ID: 8244420
[TBL] [Abstract][Full Text] [Related]
8. Design of interchain disulfide bonds in the framework region of the Fv fragment of the monoclonal antibody B3.
Jung SH; Pastan I; Lee B
Proteins; 1994 May; 19(1):35-47. PubMed ID: 8066084
[TBL] [Abstract][Full Text] [Related]
9. Conjugation of an anti-B-cell lymphoma monoclonal antibody, LL2, to long-circulating drug-carrier lipid emulsions.
Lundberg BB; Griffiths G; Hansen HJ
J Pharm Pharmacol; 1999 Oct; 51(10):1099-105. PubMed ID: 10579680
[TBL] [Abstract][Full Text] [Related]
10. Co-secretion of two distinct kappa light chains by the mu-9 hybridoma.
Krishnan IS; Hansen HJ; Gold DV; Goldenberg DM; Leung SO
Hybridoma; 1999 Aug; 18(4):325-33. PubMed ID: 10571262
[TBL] [Abstract][Full Text] [Related]
11. Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent.
Beiboer SH; Reurs A; Roovers RC; Arends JW; Whitelegg NR; Rees AR; Hoogenboom HR
J Mol Biol; 2000 Feb; 296(3):833-49. PubMed ID: 10677285
[TBL] [Abstract][Full Text] [Related]
12. Construction and expression of two mouse-human chimeric antibodies with high specificity and affinity for carcinoembryonic antigen.
Arakawa F; Haruno M; Kuroki M; Kanda H; Watanabe T; Misumi Y; Matsuoka Y
Hybridoma; 1993 Aug; 12(4):365-79. PubMed ID: 8244416
[TBL] [Abstract][Full Text] [Related]
13. Genetically engineered deglycosylation of the variable domain increases the affinity of an anti-CD33 monoclonal antibody.
Co MS; Scheinberg DA; Avdalovic NM; McGraw K; Vasquez M; Caron PC; Queen C
Mol Immunol; 1993 Oct; 30(15):1361-7. PubMed ID: 8232322
[TBL] [Abstract][Full Text] [Related]
14. Humanization of an anti-human IL-6 mouse monoclonal antibody glycosylated in its heavy chain variable region.
Sato K; Ohtomo T; Hirata Y; Saito H; Matsuura T; Akimoto T; Akamatsu K; Koishihara Y; Ohsugi Y; Tsuchiya M
Hum Antibodies Hybridomas; 1996; 7(4):175-83. PubMed ID: 9140729
[TBL] [Abstract][Full Text] [Related]
15. Position effects of variable region carbohydrate on the affinity and in vivo behavior of an anti-(1-->6) dextran antibody.
Coloma MJ; Trinh RK; Martinez AR; Morrison SL
J Immunol; 1999 Feb; 162(4):2162-70. PubMed ID: 9973491
[TBL] [Abstract][Full Text] [Related]
16. Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only.
Tamura M; Milenic DE; Iwahashi M; Padlan E; Schlom J; Kashmiri SV
J Immunol; 2000 Feb; 164(3):1432-41. PubMed ID: 10640759
[TBL] [Abstract][Full Text] [Related]
17. Epitope specificity of the anti-(B cell lymphoma) monoclonal antibody, LL2.
Stein R; Belisle E; Hansen HJ; Goldenberg DM
Cancer Immunol Immunother; 1993 Oct; 37(5):293-8. PubMed ID: 7691407
[TBL] [Abstract][Full Text] [Related]
18. Humanization of KC4G3, an anti-human carcinoma antibody.
Couto JR; Padlan EA; Blank EW; Peterson JA; Ceriani RL
Hybridoma; 1994 Jun; 13(3):215-9. PubMed ID: 7927365
[TBL] [Abstract][Full Text] [Related]
19. Carbohydrates engineered at antibody constant domains can be used for site-specific conjugation of drugs and chelates.
Qu Z; Sharkey RM; Hansen HJ; Shih LB; Govindan SV; Shen J; Goldenberg DM; Leung SO
J Immunol Methods; 1998 Apr; 213(2):131-44. PubMed ID: 9692846
[TBL] [Abstract][Full Text] [Related]
20. Cloning of cDNAs encoding the variable domains of antibody BrE-3 and construction of a chimeric antibody.
Couto JR; Blank EW; Peterson JA; Ceriani RL
Hybridoma; 1993 Feb; 12(1):15-23. PubMed ID: 8454302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
